地塞米松联合重组人血小板生成素治疗原发性免疫性血小板减少症的疗效和安全性  

Efficacy and safety of dexamethasone combined with recombinant human thrombopoietin in the treatment of idiopathic thrombocytopenic purpura

作　　者：杜金环 DU Jin-huan(Department of Hematology,Chifeng Hospital of Inner Mongolia Autonomous Region,Chifeng 024000,China)

机构地区：[1]内蒙古自治区赤峰市医院血液科,024000

出　　处：《中国实用医药》2024年第22期125-128,共4页China Practical Medicine

摘　　要：目的 分析地塞米松联合重组人血小板生成素治疗原发性免疫性血小板减少症(ITP)的疗效和安全性。方法 选取60例ITP患者,按照随机数字表法分为观察组和对照组,每组30例。观察组患者给予地塞米松联合重组人血小板生成素治疗,对照组患者给予地塞米松单独治疗。对比两组临床疗效、血小板计数、不良反应发生情况。结果 观察组总有效率为93.33%,对照组为73.33%,观察组的总有效率明显高于对照组(P<0.05)。观察组治疗前后血小板计数分别为(7.52±2.14)×109/L、(123.11±25.82)×109/L,对照组分别为(7.51±2.04)×109/L、(75.43±15.77)×109/L;治疗后,两组血小板计数均高于本组治疗前,且观察组血小板计数均显著高于对照组(P<0.05)。观察组和对照组的不良反应发生率分别为10.00%和16.67%,观察组的不良反应发生率略低于对照组,但差异无统计学意义(P>0.05)。结论 地塞米松联合重组人血小板生成素治疗ITP具有较好的疗效和安全性,可以作为一种有效的治疗方法。Objective To analyze the efficacy and safety of dexamethasone combined with recombinant human thrombopoietin in the treatment of idiopathic thrombocytopenic purpura(ITP).Methods 60 patients with ITP were selected and divided into an observation group and a control group according to random numerical table,with 30 cases in each group.The observation group was treated with dexamethasone and recombinant human thrombopoietin,and the control group was treated with dexamethasone alone.The clinical efficacy,platelet count and occurrence of adverse reactions were compared between the two groups.Results The total effective rate was 93.33% in the observation group and 73.33% in the control group;the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The platelet counts before and after treatment were(7.52±2.14)×109/L and(123.11±25.82)×109/L in the observation group,and(7.51±2.04)×109/L and(75.43±15.77)×109/L in the control group.After treatment,the platelet count in both groups was higher than that before treatment,and the platelet count in the observation group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions were 10.00% and 16.67% in the observation group and the control group;the incidence of adverse reactions in the observation group was slightly lower than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Dexamethasone combined with recombinant human thrombopoietin in the treatment of ITP has good efficacy and safety,and can be used as an effective treatment.

关 键 词：地塞米松 重组人血小板生成素 原发性免疫性血小板减少症 安全性 

分 类 号：R558.2[医药卫生—血液循环系统疾病]